Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 26 of the 50 sources its claims cite were checked for support.

Modeling mechanical activation of macrophages during pulmonary fibrogenesis for targeted anti-fibrosis therapy

Open access

Published version of a preprint

Abstract

Pulmonary fibrosis is an often fatal lung disease. Immune cells such as macrophages were shown to accumulate in the fibrotic lung, but their contribution to the fibrosis development is unclear. To recapitulate the involvement of macrophages in the development of pulmonary fibrosis, we developed a fibrotic microtissue model with cocultured human macrophages and fibroblasts. We show that profibrotic macrophages seeded on topographically controlled stromal tissues became mechanically activated. The resulting co-alignment of macrophages, collagen fibers, and fibroblasts promoted widespread fibrogenesis in micro-engineered lung tissues. Anti-fibrosis treatment using pirfenidone disrupts the polarization and mechanical activation of profibrotic macrophages, leading to fibrosis inhibition. Pirfenidone inhibits the mechanical activation of macrophages by suppressing integrin αMβ2 and Rho-associated kinase 2. These results demonstrate a potential pulmonary fibrogenesis mechanism at the tissue level contributed by macrophages. The cocultured microtissue model is a powerful tool to study the immune–stromal cell interactions and the anti-fibrosis drug mechanism.

Overview

CoChat Summary

TL;DR

The paper develops a micropillar-based coculture model of human macrophages and lung fibroblasts to show that profibrotic M2 macrophages become mechanically activated, align with collagen fibers and fibroblasts, and drive fibrogenesis. Pirfenidone inhibits this process by suppressing ROCK2 and integrin αMβ2, suggesting a macrophage-targeted anti-fibrosis mechanism.

Key findings

  • In human IPF lung tissue, CD206+ macrophages and α-SMA+ myofibroblasts were elongated and aligned; scRNA-seq reanalysis found 28 of 224 mechanotransduction genes up-regulated in IPF macrophages versus healthy donors, enriched for cell-matrix adhesion, integrin-mediated signaling, and cell motility.
  • In engineered microtissues, M2 macrophage coculture increased α-SMA expression 4.7-fold versus NHLF-only microtissues and generated 5.7 times higher contractile force than NHLF monocultures; active TGF-β was also higher in coculture supernatant.
  • Preventative pirfenidone (10 and 1000 μg/ml) reduced macrophage adhesion by 50 and 86% and α-SMA by 80 and 95%; therapeutic pirfenidone reduced macrophage adhesion by 40% and α-SMA by 47.5% but did not significantly change contractile force.
  • Pirfenidone pretreatment reduced macrophage adhesion by 59 and 72%, α-SMA by 80 and 93%, contractile force by 100% at both doses, and active TGF-β by 35 and 50%; pirfenidone suppressed ROCK2 (65 and 74% in preventative/therapeutic regimens) and integrin αM/β2 (64 and 83% in preventative/pretreatment regimens), similar to the ROCK2 inhibitor KD025.

Methods

  • Design: in vitro engineered fibrotic microtissue model with cocultured human monocyte-derived M2 macrophages and normal human lung fibroblasts (NHLFs), plus histological and single-cell RNA-seq reanalysis of human IPF lung samples.
  • Data/sample: human IPF lung tissue sections; NCBI GEO datasets GSE122960 and GSE228232 (Fig. 1D shows healthy subjects n = 8 and IPF patients n = 4 for GSE122960); peripheral blood monocytes; NHLFs; micropillar arrays in spiral, diamond, and square patterns; M2:NHLF ratio 4:1; 3-day coculture.
  • Analysis: immunofluorescence, confocal and scanning electron microscopy, micropillar deflection force measurement, TMLC reporter assay for active TGF-β, and ANOVA with Tukey tests or two-tailed paired Student’s t tests; pirfenidone and KD025 were tested in preventative, therapeutic, and pretreatment regimens.

Limitations

  • Stated: the authors note that further histological and single-cell studies on pirfenidone-treated donor lung samples are needed to determine the clinical relevancy of the ROCK2/integrin finding; they also acknowledge that in vitro CD206+ macrophages are simplified relative to the complex in vivo activation spectrum.
  • Evident: the model is entirely in vitro (human monocyte-derived M2 macrophages plus NHLFs in engineered collagen microtissues), so it cannot establish causality or efficacy in intact lung; no in vivo animal or human treatment validation is reported.
  • Evident: pirfenidone was tested at 10 and 1000 μg/ml, while the paper states the clinical serum concentration is around 10 μg/ml, so the 1000 μg/ml results are supraphysiological.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1126/sciadv.adj9559

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Mechanical activation of lung macrophages in a highly remodeled fibrotic tissue microenvironment. (A) Hematoxylin and eosin (H&E) staining of a highly remodeled region in a fibrotic lung tissue. (B) Confocal fluorescence images of α-SMA and CD206 of a matching region in an adjacent tissue section. Both α-SMA+ myofibroblasts and CD206+ macrophages adopted elongated morphology and aligned with each other. Scale bars, 100 μm. (C) t-Distributed stochastic neighbor embedding (t-SNE) plot showing the distinct populations of alveolar macrophages in patients with IPF and healthy donors. (D) t-SNE plot showing the preferential expression of ITGAM gene in alveolar macrophages in the patients with IPF illustrated in (C). Data extracted from healthy subjects (n = 8) and patients with IPF (n = 4) based on NCBI GEO dataset GSE122960. (E) Expression of genes linked to the activation of mechanobiological pathways in alveolar macrophages of healthy donors (blue) and patients with IPF (orange). Bubble size corresponds to the average expression level of the gene within each group. The data were extracted from the NCBI GEO datasets GSE122960 and GSE228232. (F) Fold enrichment of Gene Ontology (GO) biological process in genes that are up-regulated in fibrotic lungs compared to healthy donor lungs. The GO enrichment data were collected from dataset GSE122960.
Fig. 1. Mechanical activation of lung macrophages in a highly remodeled fibrotic tissue microenvironment. (A) Hematoxylin and eosin (H&E) staining of a highly remodeled region in a fibrotic lung tissue. (B) Confocal fluorescence images of α-SMA and CD206 of a matching region in an adjacent tissue section. Both α-SMA+ myofibroblasts and CD206+ macrophages adopted elongated morphology and aligned with each other. Scale bars, 100 μm. (C) t-Distributed stochastic neighbor embedding (t-SNE) plot showing the distinct populations of alveolar macrophages in patients with IPF and healthy donors. (D) t-SNE plot showing the preferential expression of ITGAM gene in alveolar macrophages in the patients with IPF illustrated in (C). Data extracted from healthy subjects (n = 8) and patients with IPF (n = 4) based on NCBI GEO dataset GSE122960. (E) Expression of genes linked to the activation of mechanobiological pathways in alveolar macrophages of healthy donors (blue) and patients with IPF (orange). Bubble size corresponds to the average expression level of the gene within each group. The data were extracted from the NCBI GEO datasets GSE122960 and GSE228232. (F) Fold enrichment of Gene Ontology (GO) biological process in genes that are up-regulated in fibrotic lungs compared to healthy donor lungs. The GO enrichment data were collected from dataset GSE122960.CC BY · PubMed Central
Fig. 2. Macrophage mechanical activation in response to topographically controlled tissue remodeling. Phase contrast images of fibroblast and macrophage cocultured lung microtissues formed on a group of flexible micropillars arranged in a spiral pattern (A), a diamond pattern (B), and a square pattern (C). Confocal reflectance images of collagen fibers (cyan) and fluorescence images of CD206 (red) of spiral patterned (D), diamond patterned (E), and square patterned (F) microtissues. (G to I) Enlarged views of boxed regions in (D) to (F) showing the co-alignment between the CD206-positive macrophages and the collagen fibers. (J) Scanning electron microscopy (SEM) images of a fibroblast only microtissue showing the fibroblast alignment. (K) SEM images of a cocultured microtissue showing the co-alignment between fibroblasts and macrophages.
Fig. 2. Macrophage mechanical activation in response to topographically controlled tissue remodeling. Phase contrast images of fibroblast and macrophage cocultured lung microtissues formed on a group of flexible micropillars arranged in a spiral pattern (A), a diamond pattern (B), and a square pattern (C). Confocal reflectance images of collagen fibers (cyan) and fluorescence images of CD206 (red) of spiral patterned (D), diamond patterned (E), and square patterned (F) microtissues. (G to I) Enlarged views of boxed regions in (D) to (F) showing the co-alignment between the CD206-positive macrophages and the collagen fibers. (J) Scanning electron microscopy (SEM) images of a fibroblast only microtissue showing the fibroblast alignment. (K) SEM images of a cocultured microtissue showing the co-alignment between fibroblasts and macrophages.CC BY · PubMed Central
Fig. 3. Extensive co-alignment between macrophages and fibroblasts promoted a widespread fibrosis response in the microtissue. (A) Schematic showing the fibrosis induction in NHLF-populated microtissues by pro-fibrotic macrophages. (B) Representative fluorescence images of NHLF only (untreated), TGF-β1–treated NHLF only, and M2 macrophage and NHLF cocultured microtissues (left to right). Microtissues were stained for nuclei (blue), α-SMA (green) and CD206 (red). Scale bar, 200 μm. (C) Fluorescence intensity measurement of α-SMA for different microtissue culture conditions. a.u., arbitrary units; ns, not significant. (D) Contractile force measurement for different microtissue culture conditions. (E) Supernatant active TGF-β level for different microtissue culture conditions. (F) Enlarged view of the boxed region in (B) showing the co-alignment between single myofibroblasts and M2 macrophages. (G) Enlarged view shows positive TGF-β signal co-localizing with CD206 but not with α-SMA. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 when compared to untreated group by one-way ANOVA with Tukey test; 'ns' indicates no significance between two treatment groups using a two-tailed paired Student's t test.
Fig. 3. Extensive co-alignment between macrophages and fibroblasts promoted a widespread fibrosis response in the microtissue. (A) Schematic showing the fibrosis induction in NHLF-populated microtissues by pro-fibrotic macrophages. (B) Representative fluorescence images of NHLF only (untreated), TGF-β1–treated NHLF only, and M2 macrophage and NHLF cocultured microtissues (left to right). Microtissues were stained for nuclei (blue), α-SMA (green) and CD206 (red). Scale bar, 200 μm. (C) Fluorescence intensity measurement of α-SMA for different microtissue culture conditions. a.u., arbitrary units; ns, not significant. (D) Contractile force measurement for different microtissue culture conditions. (E) Supernatant active TGF-β level for different microtissue culture conditions. (F) Enlarged view of the boxed region in (B) showing the co-alignment between single myofibroblasts and M2 macrophages. (G) Enlarged view shows positive TGF-β signal co-localizing with CD206 but not with α-SMA. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 when compared to untreated group by one-way ANOVA with Tukey test; 'ns' indicates no significance between two treatment groups using a two-tailed paired Student's t test.CC BY · PubMed Central
Fig. 4. The effect of preventative anti-fibrosis treatment on cocultured microtissue. (A) Schematic showing the preventative anti-fibrosis treatment and results evaluation. PFD was administrated at the beginning of the coculture. (B) Representative fluorescence images of cocultured microtissues treated with PFD (0, 10, or 1000 μg/ml) (left to right). Scale bar, 200 μm. (C) The number of macrophages adhered on the microtissue under different PFD treatments. (D) Fluorescence intensity measurement of α-SMA under different PFD treatment conditions. (E) Contractile force measurement under different PFD treatment conditions. (F) Supernatant active TGF-β level under different PFD treatment conditions. *P ≤ 0.05 and ***P ≤ 0.001 when compared with untreated group by one-way ANOVA with Tukey test; #P ≤ 0.05, ##P ≤ 0.01, and ###P ≤ 0.001 when comparison were performed between treatment groups using a two-tailed paired Student's t test.
Fig. 4. The effect of preventative anti-fibrosis treatment on cocultured microtissue. (A) Schematic showing the preventative anti-fibrosis treatment and results evaluation. PFD was administrated at the beginning of the coculture. (B) Representative fluorescence images of cocultured microtissues treated with PFD (0, 10, or 1000 μg/ml) (left to right). Scale bar, 200 μm. (C) The number of macrophages adhered on the microtissue under different PFD treatments. (D) Fluorescence intensity measurement of α-SMA under different PFD treatment conditions. (E) Contractile force measurement under different PFD treatment conditions. (F) Supernatant active TGF-β level under different PFD treatment conditions. *P ≤ 0.05 and ***P ≤ 0.001 when compared with untreated group by one-way ANOVA with Tukey test; #P ≤ 0.05, ##P ≤ 0.01, and ###P ≤ 0.001 when comparison were performed between treatment groups using a two-tailed paired Student's t test.CC BY · PubMed Central
Fig. 5. The effect of therapeutic anti-fibrosis treatment on cocultured microtissue. (A) Schematic showing the therapeutic anti-fibrosis treatment and results evaluation. PFD was administrated after 3 days of coculture. (B) Representative fluorescence images of cocultured microtissues treated with PFD (1000 μg/ml). Scale bar, 200 μm. (C) The number of macrophages adhered on the microtissue under different PFD conditions. (D) Fluorescence intensity measurement of α-SMA under different PFD treatment conditions. (E) Contractile force measurement under different PFD treatment conditions. (F) Supernatant active TGF-β level under different PFD treatment conditions. ***P ≤ 0.001 when compared with untreated group by one-way ANOVA with Tukey test; 'ns' indicates no significance between two treatment groups using a two-tailed paired Student's t test.
Fig. 5. The effect of therapeutic anti-fibrosis treatment on cocultured microtissue. (A) Schematic showing the therapeutic anti-fibrosis treatment and results evaluation. PFD was administrated after 3 days of coculture. (B) Representative fluorescence images of cocultured microtissues treated with PFD (1000 μg/ml). Scale bar, 200 μm. (C) The number of macrophages adhered on the microtissue under different PFD conditions. (D) Fluorescence intensity measurement of α-SMA under different PFD treatment conditions. (E) Contractile force measurement under different PFD treatment conditions. (F) Supernatant active TGF-β level under different PFD treatment conditions. ***P ≤ 0.001 when compared with untreated group by one-way ANOVA with Tukey test; 'ns' indicates no significance between two treatment groups using a two-tailed paired Student's t test.CC BY · PubMed Central
Fig. 6. The effect of anti-fibrosis pretreatment on cocultured microtissue. (A) Schematic showing the anti-fibrosis pretreatment and results evaluation. Macrophages were pretreated with PFD for 24 hours and then added to NHLF microtissues to form the coculture. (B) Representative fluorescence images of cocultured microtissues treated with PFD (0, 10 or 1000 μg/ml) (left to right). Scale bar, 200 μm. (C) The number of macrophages adhered on the microtissue under different PFD conditions. (D) Fluorescence intensity measurement of α-SMA under different PFD treatment conditions. (E) Contractile force measurement under different PFD treatment conditions. (F) Supernatant active TGF-β level under different PFD treatment conditions. **P ≤ 0.01, and ***P ≤ 0.001 when compared with untreated group by one-way ANOVA with Tukey test; #P ≤ 0.05 and ###P ≤ 0.001 when comparison were performed between treatment groups using a two-tailed paired Student's t test.
Fig. 6. The effect of anti-fibrosis pretreatment on cocultured microtissue. (A) Schematic showing the anti-fibrosis pretreatment and results evaluation. Macrophages were pretreated with PFD for 24 hours and then added to NHLF microtissues to form the coculture. (B) Representative fluorescence images of cocultured microtissues treated with PFD (0, 10 or 1000 μg/ml) (left to right). Scale bar, 200 μm. (C) The number of macrophages adhered on the microtissue under different PFD conditions. (D) Fluorescence intensity measurement of α-SMA under different PFD treatment conditions. (E) Contractile force measurement under different PFD treatment conditions. (F) Supernatant active TGF-β level under different PFD treatment conditions. **P ≤ 0.01, and ***P ≤ 0.001 when compared with untreated group by one-way ANOVA with Tukey test; #P ≤ 0.05 and ###P ≤ 0.001 when comparison were performed between treatment groups using a two-tailed paired Student's t test.CC BY · PubMed Central
Fig. 7. PFD suppresses macrophage mechanical activation through inhibition of ROCK2 and integrin αMβ2. (A) Representative immunofluorescence images of macrophage and fibroblast cocultured microtissues under PFD or ROCK2 inhibitor KD025 treatments. Microtissues were stained for CD206 (red), ROCK2 (yellow), and nuclei (blue) from top to bottom. Fluorescence intensity measurement of ROCK2 in cocultured microtissues under preventative treatment (B) and therapeutic treatment (C). Number of adherent macrophages on cocultured microtissues under preventative treatment (D) and therapeutic treatment (E). Active TGF-β in cell culture supernatant under preventative treatment (F) and therapeutic treatment (G). (H) Representative immunofluorescence images of macrophage and fibroblast cocultured microtissues under different PFD treatment conditions. Microtissues were stained for CD11b (green), CD18 (yellow), and CD206 (red) from top to bottom. Fluorescence intensity measurement of CD11b (I) and CD18 (J) under treatments with or without PFD. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 when compared with untreated group by one-way ANOVA with Tukey test; 'ns' indicates no significance between two treatment groups using a two-tailed paired Student's t-test; #P ≤ 0.05 and ##P ≤ 0.01 between two treatment groups using a two-tailed paired Student's t test.
Fig. 7. PFD suppresses macrophage mechanical activation through inhibition of ROCK2 and integrin αMβ2. (A) Representative immunofluorescence images of macrophage and fibroblast cocultured microtissues under PFD or ROCK2 inhibitor KD025 treatments. Microtissues were stained for CD206 (red), ROCK2 (yellow), and nuclei (blue) from top to bottom. Fluorescence intensity measurement of ROCK2 in cocultured microtissues under preventative treatment (B) and therapeutic treatment (C). Number of adherent macrophages on cocultured microtissues under preventative treatment (D) and therapeutic treatment (E). Active TGF-β in cell culture supernatant under preventative treatment (F) and therapeutic treatment (G). (H) Representative immunofluorescence images of macrophage and fibroblast cocultured microtissues under different PFD treatment conditions. Microtissues were stained for CD11b (green), CD18 (yellow), and CD206 (red) from top to bottom. Fluorescence intensity measurement of CD11b (I) and CD18 (J) under treatments with or without PFD. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 when compared with untreated group by one-way ANOVA with Tukey test; 'ns' indicates no significance between two treatment groups using a two-tailed paired Student's t-test; #P ≤ 0.05 and ##P ≤ 0.01 between two treatment groups using a two-tailed paired Student's t test.CC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 3 Not valid · 12 Not checked · 85 Own results and interpretations

66 more claims · 8 with their cited sources checked

Create a free account to see all 114 claims and to verify the 24 references still open.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 36

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 62 references

Cited by

See all 68

Metadata

Authors
Xu, Y., Ying, L., Lang, J. K., Hinz, B., & Zhao, R.
Affiliations
  • University at Buffalo, State University of New York (US)
  • VA Western New York Healthcare System (US)
  • St. Michael's Hospital (CA)
Corresponding author
Zhao, Ruogang
Venue
Science Advances
Published
2024-03-29
Volume
10
Issue
13
Pages
eadj9559-eadj9559
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4393319429
Cited by
67
References
62
Citations by year
2026: 33 · 2025: 31 · 2024: 3
FWCI
19.46
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion)
Funders
  • York University
  • National Institutes of Health
  • University at Buffalo
  • NYU Grossman School of Medicine
  • Canadian Institutes of Health Research (375597)
  • National Heart, Lung, and Blood Institute (R33HL154117, R01HL163428)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
pulmonary fibrosis, macrophages, mechanical activation, fibrogenesis, macrophage polarization, pirfenidone, Mac-1, collagen fiber alignment, antifibrotic therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modeling mechanical activation of macrophages during pulmonary fibrogenesis for targeted anti-fibrosis therapy. https://app.cochat.ai/papers/10.1126/sciadv.adj9559
The paper
Xu, Y., Ying, L., Lang, J. K., Hinz, B., & Zhao, R. (2024). Modeling mechanical activation of macrophages during pulmonary fibrogenesis for targeted anti-fibrosis therapy. Science Advances. https://doi.org/10.1126/sciadv.adj9559

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.